{"id":11187,"date":"2023-11-24T01:07:00","date_gmt":"2023-11-23T17:07:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11187"},"modified":"2024-11-04T01:10:43","modified_gmt":"2024-11-03T17:10:43","slug":"simcere-pharmaceutical-secures-rights-to-develop-rademikibart-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11187","title":{"rendered":"Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China"},"content":{"rendered":"\n<p>China\u2019s Simcere Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/2096:HKG\">HKG: 2096<\/a>) has entered into an agreement to acquire the rights to develop the anti-inflammatory monoclonal antibody rademikibart from US-based Connect Biopharma Holdings Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/CNTB:NASDAQ\">NASDAQ: CNTB<\/a>). The deal, negotiated with Connect Bio\u2019s China-based subsidiaries, Connect Biopharma Hong Kong Ltd and Suzhou Connect Biopharma Co., Ltd, includes an upfront fee of RMB 150 million (USD 21 million), potential development and commercial milestones of up to RMB 875 million (USD 120 million), and double-digit percentage royalties on future net sales.<\/p>\n\n\n\n<p><strong>Greater China Development and Commercialization Rights<\/strong><\/p>\n\n\n\n<p>Simcere will assume development, manufacturing, and commercial rights for rademikibart across the Greater China region, encompassing mainland China, Hong Kong, Macau, and Taiwan. Connect Bio has already initiated clinical trials for the drug candidate in China and will oversee them to completion. Simcere is expected to handle the New Drug Application (NDA) filing, with an anticipated completion in Q1 2024.<\/p>\n\n\n\n<p><strong>Rademikibart&#8217;s Potential in Th2 Driven Inflammatory Diseases<\/strong><\/p>\n\n\n\n<p>Rademikibart is a human monoclonal antibody targeting IL-4R\u03b1, a common subunit for IL-4R and IL-13 receptors, and is in development for the treatment of Th2 driven inflammatory diseases, including atopic dermatitis. With a dosing frequency of once every 4 weeks, the molecule is considered to have the potential for best-in-class status.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2019s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[248,1099,1041,271],"class_list":["post-11187","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-connect-biopharma","tag-hkg-2096","tag-nasdaq-cntb","tag-simcere-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the rights to develop the anti-inflammatory monoclonal antibody rademikibart from US-based Connect Biopharma Holdings Ltd (NASDAQ: CNTB). The deal, negotiated with Connect Bio\u2019s China-based subsidiaries, Connect Biopharma Hong Kong Ltd and Suzhou Connect Biopharma Co., Ltd, includes an upfront fee of RMB 150 million (USD 21 million), potential development and commercial milestones of up to RMB 875 million (USD 120 million), and double-digit percentage royalties on future net sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11187\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11187\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-23T17:07:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-03T17:10:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11187#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11187\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China\",\"datePublished\":\"2023-11-23T17:07:00+00:00\",\"dateModified\":\"2024-11-03T17:10:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11187\"},\"wordCount\":217,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Connect Biopharma\",\"HKG: 2096\",\"NASDAQ: CNTB\",\"Simcere Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11187#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11187\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11187\",\"name\":\"Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-23T17:07:00+00:00\",\"dateModified\":\"2024-11-03T17:10:43+00:00\",\"description\":\"China\u2019s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the rights to develop the anti-inflammatory monoclonal antibody rademikibart from US-based Connect Biopharma Holdings Ltd (NASDAQ: CNTB). The deal, negotiated with Connect Bio\u2019s China-based subsidiaries, Connect Biopharma Hong Kong Ltd and Suzhou Connect Biopharma Co., Ltd, includes an upfront fee of RMB 150 million (USD 21 million), potential development and commercial milestones of up to RMB 875 million (USD 120 million), and double-digit percentage royalties on future net sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11187#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11187\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11187#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the rights to develop the anti-inflammatory monoclonal antibody rademikibart from US-based Connect Biopharma Holdings Ltd (NASDAQ: CNTB). The deal, negotiated with Connect Bio\u2019s China-based subsidiaries, Connect Biopharma Hong Kong Ltd and Suzhou Connect Biopharma Co., Ltd, includes an upfront fee of RMB 150 million (USD 21 million), potential development and commercial milestones of up to RMB 875 million (USD 120 million), and double-digit percentage royalties on future net sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11187","og_locale":"en_US","og_type":"article","og_title":"Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11187","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-23T17:07:00+00:00","article_modified_time":"2024-11-03T17:10:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11187#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11187"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China","datePublished":"2023-11-23T17:07:00+00:00","dateModified":"2024-11-03T17:10:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11187"},"wordCount":217,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Connect Biopharma","HKG: 2096","NASDAQ: CNTB","Simcere Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11187#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11187","url":"https:\/\/flcube.com\/?p=11187","name":"Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-23T17:07:00+00:00","dateModified":"2024-11-03T17:10:43+00:00","description":"China\u2019s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the rights to develop the anti-inflammatory monoclonal antibody rademikibart from US-based Connect Biopharma Holdings Ltd (NASDAQ: CNTB). The deal, negotiated with Connect Bio\u2019s China-based subsidiaries, Connect Biopharma Hong Kong Ltd and Suzhou Connect Biopharma Co., Ltd, includes an upfront fee of RMB 150 million (USD 21 million), potential development and commercial milestones of up to RMB 875 million (USD 120 million), and double-digit percentage royalties on future net sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11187#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11187"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11187#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11187"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11187\/revisions"}],"predecessor-version":[{"id":11188,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11187\/revisions\/11188"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}